Folks, a review of my ARNA Targets- which still stand:
(We hit $13.50 on approval- I had forecast $12.50 but anticipated it would be somewhat higher, as you will see below.)
Thursday, June 21, 2012 9:39:11 AM Re: MiamiGent post# 14320 Post # of 15241
ARNA Target Update (first since original):
Previous Targets: upon anticipated FDA approval June 27th- $11. By end of year- $22.
New Targets: Upon anticipated approval June 27th- $12.50 By end of year- $25.
These are the numbers I can justify based on current production capability, marketing arrangements, revenue sharing, trade interest and share structure. Of course, these projections presuppose FDA approval.
Considerable interest has built since the FDA Advisory Committee's convincing recommendation in May to approve Arena Pharmaceutical's (ARNA) diet drug candidate "Lorcaserin". In recent days, interest might be described as frenzied- and not without some justification.
I happily look forward to my nearby projection being shattered due to phenomenal interest. My primary interest is how high up the beach the share price reaches rather than how high the preceeding wave will be- though it'll be fun and may offer opportunities to finesse for profit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.